About Acura

Our goal is to become a leading specialty pharmaceutical company focused on addressing the growing societal problem of prescription drug abuse by developing a broad portfolio of pharmaceutical products with abuse deterrent features and benefits. Specifically, we intend to:

• Capitalize on our Experience and Expertise in the Research and Development of Pharmaceutical Products with Abuse Deterrent Features and Benefits. Our strategy is to facilitate rapid product development and minimize risk by utilizing active pharmaceutical ingredients with proven safety and efficacy profiles with known potential for abuse, and develop new products utilizing our proprietary Aversion® Technology using the FDA’s 505(b)(2) regulatory process.
• Emerge as a Leader in Developing and Commercializing Products with Abuse Deterrent Features and Benefits Able to Uniquely Address the Growing Problem of Abuse of Prescription Drugs. We believe that Acurox® and our other product candidates in development have demonstrated that Aversion® Technology allows products to provide the analgesic benefit they were intended to deliver, while simultaneously having features that are intended to deter misuse and abuse.
• Optimize Shareholder Value and Temper Risk by Licensing our Product Candidates to Strategically Focused Pharmaceutical Companies in the U.S. and Other Geographic Territories. By licensing our product candidates for milestone fees and royalties to strategically focused companies with expertise and infrastructure in commercialization of pharmaceuticals, we are able to leverage our expertise, intellectual property rights and Aversion® Technology without the need to build costly sales and manufacturing infrastructure.
• Apply our Aversion® and Impede™ Technologies to Non-Opioid Products that are Subject to Abuse. We intend to first develop a broad pipeline of opioid analgesic products, and thereafter we intend to expand our portfolio to other pharmaceutical product categories containing potentially abuseable active ingredients such as tranquillizers (brand products such as Valium®, Xanax®, Halcion® and Ativan®), stimulants (brand products such as Dexedrine®, Adderall®, Ritalin® and Concerta®) and sedatives (brand products such as Nembutal®, Butisol®, and Seconal®).
• Maintain our Efficient Internal Cost Structure. We maintain a streamlined corporate infrastructure focused on: (i) selection, formulation development, laboratory evaluation, manufacture, quality assurance and stability testing of certain finished dosage form product candidates; (ii) development and prosecution of our patent applications; and (iii) negotiation and execution of license and development agreements with strategically focused pharmaceutical companies. We outsource the high cost elements of clinical development and commercialization.